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Abstract
Trypanosoma brucei (T.b.) rhodesiense is the cause of the acute form of human African try-
panosomiasis (HAT) in eastern and southern African countries. There is some evidence
that there is diversity in the disease progression of T.b. rhodesiense in different countries.
HAT in Malawi is associated with a chronic haemo-lymphatic stage infection compared to
other countries, such as Uganda, where the disease is acute with more marked neurological
impairment. This has raised the question of the role of host genetic factors in infection out-
comes. A candidate gene association study was conducted in the northern region of Malawi.
This was a case-control study involving 202 subjects, 70 cases and 132 controls. All individ-
uals were from one area; born in the area and had been exposed to the risk of infection
since birth. Ninety-six markers were genotyped from 17 genes: IL10, IL8, IL4, HLA-G,
TNFA, IL6, IFNG, MIF, APOL, HLA-A, IL1B, IL4R, IL12B, IL12R, HP, HPR, and CFH.
There was a strong significant association with APOL1 G2 allele (p = 0.0000105, OR = 0.14,
CI95 = [0.05–0.41], BONF = 0.00068) indicating that carriers of the G2 allele were protected
against T.b. rhodesiense HAT. SNP rs2069845 in IL6 had raw p < 0.05, but did not remain
significant after Bonferroni correction. There were no associations found with the other 15
candidate genes. Our finding confirms results from other studies that the G2 variant of
APOL1 is associated with protection against T.b. rhodesiense HAT.
Author summary
Though some work has been done on the genetics of trypanosome infections in animals,
relatively little is known about the genetics of human African trypanosomiasis (HAT)
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infections. To test whether any variants are associated with reduced or increased risk of
trypanosomiasis, 96 variants in 17 genes were genotyped in patients diagnosed with T. b.
rhodesiense HAT and individuals without the disease in this study. From the 96 variants,
only one variant G2 in the APOL1 gene was found to be strongly associated with protec-
tion from trypanosomiasis. The results reported here will contribute to the knowledge of
the role of human genetics in disease progression, which could offer opportunities for
development of much needed new diagnostics and intervention strategies.
Introduction
Human African trypanosomiasis (HAT), also known as sleeping sickness, is one of the major
neglected infectious diseases. Sleeping sickness is endemic in 36 African countries and over 60
million people are at risk of being infected [1]. HAT is more prevalent in rural areas where health
care is scarce and affects mainly individuals of reproductive age, increasing their poverty [2].
HAT is a vector-borne parasitic disease transmitted by tsetse flies of the genus Glossina. It
is caused by two subspecies of the single-celled parasite Trypanosoma brucei: T.b. rhodesiense
found in eastern and southern Africa, with reservoirs in livestock and wildlife, and T.b. gam-
biense found in central and western Africa, which causes the majority of human cases with the
main reservoir being humans [2,3]. Sleeping sickness has two clinical stages; the haemolym-
phatic stage followed by the meningoencephalitic stage. The two subspecies have different
rates of disease progression; T.b. rhodesiense infection is typically described as an acute disease
with rapid progression to late stage and T.b. gambiense progresses more slowly [3].
Untreated HAT infections are believed to be 100% fatal, with death occurring within weeks
or months of symptoms first appearing [4,5]. However, there is increasing evidence that infec-
tion by T.b. rhodesiense can result in a wide range of clinical outcomes in its human host [6–8].
Furthermore, there is evidence that individuals from non-endemic areas suffer a more severe
infection than people from endemic areas [9,10]. Similar variation in disease progression is
also observed in infections with T.b. gambiense [11,12]. Some infected people in Guinea and
Coˆte d’Ivoire progressed to self-cure after refusing treatment, and other individuals in endemic
foci in West Africa have shown trypanotolerance analogous to that observed in some West
African cattle breeds and in mouse models [13–18].
Genetic polymorphisms in T. b. gambiense as well as the human host have been shown to
contribute to different responses to infection [19–21]. Genes involved in immune responses
and regulating immunity play important roles in infection outcomes. One such gene is Apo-
lipoprotein-L1 (APOL1) whose variants G1 and G2 are associated with kidney disease in Afri-
can Americans and have been predicted to have been selected because they provide protection
against HAT [22,23]. APOL1 lyses trypanosomes by depolarizing the parasite lysosomal mem-
brane, which leads to osmotic swelling and rupture of the lysosome and then lysis of the try-
panosome [24–28]. Trypanosoma brucei rhodesiense can infect humans because they express
the serum-resistance-associated (SRA) protein, which binds to the SRA-interacting domain
of APOL1 resulting in the loss of APOL1 lytic function [24–30]. It has been shown that serum
containing G1 and G2 alleles of APOL1 is lytic to T.b. rhodesiense in vitro, whilst the parasites
are resistant to serum containing the G0 allele [22], but evidence that these alleles of APOL1
mediate resistance to parasites in vivo is less conclusive. The G2 allele has been associated with
protection against T.b. rhodesiense HAT in one study in Uganda but not in another, and no
associations have been found between carriage of the G1 allele and reduced risk of developing
T.b. rhodesiense HAT [31,32].
APOL1 association with Trypanosoma brucei rhodesiense
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Other genes have also been implicated in the response to infection with T. brucei spp. Two
candidate gene association studies in the Democratic Republic of Congo (DRC) have shown
association with the disease and alleles of four genes (IL6, HLA-G, IL10 and APOL1) out of the
10 genes (IL1A, IL4, IL6, IL8, IL10, TNFA, IFNG, HLA-G, HPR and APOL1) studied [21,33].
In other studies, cytokine levels have shown significant association with HAT infections, but
the genetic factors regulating this response have not been identified [8,33–37]. In the present
study, we investigated the role of single nucleotide polymorphisms in 17 genes (IL10, IL8,
IL4, HLA-G, TNFA, IL6, IFNG, MIF, APOL1 HLA-A, IL1B, IL4R, IL12B, IL12R, HP, HPR and
CFH) for association with susceptibility to HAT using a case-control study design on subjects
from the northern part of Malawi.
Materials and methods
Population and study design
The samples came from the Rumphi District in northern Malawi (Fig 1), where the prevalence
of HAT cases is highest in Malawi. Between 2000 and 2006, 150 people were confirmed to have
died of HAT in Rumphi district alone [38,39].
Cases were identified through active and passive surveys. Hospital case files were checked
for previously diagnosed HAT patients and were followed up in their communities. All these
cases had been treated with Suramin I.V 20 mg/kg body weight for 23 days and Melarsoprol I.
V 3.6 mg/kg body weight for 23 days for the early and late stage of HAT respectively according
to Malawi HAT Treatment Guidelines S1 Table. They were then followed up at 3, 6, and 12
months after discharge for review S1 Table. The active screening was conducted during the
follow-up of HAT cases. After taking a history and an examination related to HAT infection,
venous blood was collected in heparinized tubes and taken to the laboratory at a temperature
of 4˚C. Eight capillary tubes were prepared from each sample and the buffy coat was examined
by microscopy. Out of 350 people screened, 243 individuals entered the study [40]. Cases were
defined as individuals in whom trypanosomes were detected by microscopy in blood, lym-
phatic fluid or cerebral spinal fluids (CSF). Controls were defined as individuals with no signs
and symptoms suggestive of HAT and no trypanosomes detected from the blood.
A total of 202 samples, 70 cases and 132 controls were genotyped. Cases and controls came
from the same area, were born in the area and had been exposed to infection since birth.
Ethics statement
The protocol was approved by the Malawi National Health Sciences Research Committee, pro-
tocol numbers NHSRC 15/4/1399 and Malawi 1213. There was also local involvement of all
stakeholders, and local leaders gave approval for the study to be carried out in the area. All
individuals enrolled in the study were 18 years of age or older. All individuals signed informed
consent forms in their native language.
Power analysis
This study was one of six studies of populations of HAT endemic areas in Cameroon, Cote
d’Ivoire, Guinea, Malawi, Democratic Republic of Congo (DRC), and Uganda. The studies
were designed to have: 80% power to detect odds ratios (OR) >2 for loci with disease allele fre-
quencies of 0.15–0.65; and 100 cases; 100 controls with the 96 SNPs genotyped.
This study had 132 controls, 70 cases from our study area, and had 80% power to detect an
OR>2 with disease allele frequencies of 0.1–0.75 with the 96 SNPs genotyped. Power calcula-
tions were undertaken using the genetics analysis package gap in R [41–43].
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DNA extraction
DNA was extracted from whole blood (collected in heparin vacutainer tubes (BD) during sur-
vey), using Qiagen DNeasy Blood & Tissue Kit (Crawley, UK) as per the manufacturer’s
instructions. Extracted DNA samples were temporarily stored at -20˚C.
Fig 1. Map of Malawi showing Rumphi District.
https://doi.org/10.1371/journal.pntd.0007603.g001
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Genes selection
Genes were selected based on prior knowledge of their role in the development of HAT. The
following genes were selected: IL10, IL8, IL4, HLAG, TNFA, IL6, IFNG, MIF, APOL, HLAA,
IL1B, IL4R, IL12B, IL12R, HP, HPR, and CFH [20–22,31,33,36,44–53].
SNP selection
Ninety-six SNPs were selected for genotyping using two strategies: 1) SNPs that had been previ-
ously reported to be associated with HAT or 2) by scanning for sets of linked marker SNP (r2
<0.5) across each of IL4, IL8, IL6, HLAG, MIF and IFNG. The SNPs in this second group of
genes were selected using a merged SNP dataset obtained from low fold coverage (8-10x) whole
genome shotgun data generated from 230 residents living in regions (DRC, Guinea Conakry,
Ivory Coast and Uganda) where trypanosomiasis is endemic (TrypanoGEN consortium,
sequences at European Nucleotide Archive Study: EGAS00001002602) and 1000 Genomes
Project data from African populations [54]. PLINK v1.9 package (https://www.cog-genomics.
org/plink/1.9/) [55] was used to estimate linkage disequilibrium (LD) (r2) between loci and all
sets of SNPs covering the gene were identified. Loci that were excluded during assay develop-
ment or failed to be genotyped were not replaced and hence not all regions of each gene were
linked to marker SNP. S2 Table shows the candidate genes and SNPs selected for this study.
SNP genotyping
Samples were genotyped by two commercial service providers: INRA- Site de Pierroton, Plate-
forme Genome Transcriptome de Bordeaux, France and LGC Genomics, Hoddesden, UK. At
INRA, two sets of 40 SNP assays were designed using Assay Design Suite v2.0 (Agena Biosci-
ences). SNPs were genotyped with the iPLEX Gold genotyping kit (Agena Biosciences) for the
MassArray iPLEX genotyping assay, following the manufacturer’s instructions. Products were
detected on a MassArray mass spectrophotometer and data were acquired in real time with
MassArray RT software (Agena Biosciences). SNP clustering and validation was carried out
with Typer 4.0 software (Agena Biosciences). LGC Genomics genotyped all SNPs that failed
genotyping at INRA and some additional SNPs using the PCR based KASP assay [56].
Data analysis
Plink 1.9 [55] was used for data analysis and R version 3.3.1 (2016-06-21)—"Bug in Your Hair"
was used for data visualization (R Foundation for Statistical Computing, Vienna Austria). The
data from genotyping were converted to PLINK format and were tested for data completeness,
allele frequencies, LD, and Hardy-Weinberg equilibrium (HWE). Individuals and SNP loci
with more than 15% and 20% missing data respectively, were removed from the analysis. Fish-
er’s exact test [57] in PLINK was used for testing the association of SNPs with HAT. One of
each pair of SNPs with post genotyping linkage r2 > 0.5 were excluded. This increased the
power of analysis by reducing the number of tests. Multiple testing was corrected for using a
Bonferroni corrected p-value of 0.00077 (0.05/65) [58] and the Benjamini Hochberg false dis-
covery rate (FDR) was used to estimate the probability that the null hypothesis of no associa-
tion should not be rejected [58,59].
Results
Two hundred and two samples were sent for genotyping. There were 143 males (70%) and 59
females (30%) with 70 cases (35%) and 132 (65%) controls. The mean ages of the cases and
controls were 45 and 41 respectively.
APOL1 association with Trypanosoma brucei rhodesiense
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Ninety-six SNPs were genotyped from 17 genes (see Plink MAP and PED files S1 and S2
Data). After the data was cleaned, 26 individuals with more than 15% missing data were fil-
tered out leaving 176; 59 cases and 117 controls. Nine SNPs with more than 20% missing data
were filtered out leaving 87 (see S1 and S2 Figs). Four SNPs, which were not in HWE, were
removed. A cut-off of HWE p-value of 1 x 10−8 was used and genotype scatter plots were
checked for allele clusters.
To increase the power of analysis, 18 SNPs, which were linked to each other (r2 > 0.5), were
excluded by pruning (by working across the loci in windows of five SNPs moving one SNP at a
time and excluding one of each pair of SNPs with LD greater than r2 = 0.5). After quality con-
trol and linkage pruning, 65 SNPs were left for association analysis. See S3 Table showing fil-
tered data, and S4 Table showing pruned SNPs.
Results of case-control studies can be confounded by population structure. Most of the
cases and controls (95%) were Tumbuka speakers, however there were speakers of five other
languages in the cases (3) and controls (8) (Table 1). If the minor language speakers had differ-
ent allele frequencies from the Tumbuka, this could affect the results.
Association study
The Fisher’s exact test was used to compare allele frequencies in cases and controls. Allele fre-
quencies differed at two SNPs in two genes (APOL1 and IL6) between the cases and controls.
However, only rs71785313 (G2) in APOL1 (OR 0.14) remained significant after Bonferroni
correction (threshold p = 0.00077) and after Benjamini-Hochberg FDR correction, as shown
in Table 2. Complete results for all loci are shown in S5 Table. The data was also analysed
Table 1. Numbers of speakers of each language represented in the sample.
Language Cases Controls Total
Tumbuka 67 124 191
Chewa 1 4 5
Senga 1 0 1
Ngoni 1 2 3
Sena 0 1 1
Lomwe 0 1 1
Total 70 132 202
https://doi.org/10.1371/journal.pntd.0007603.t001
Table 2. Association analysis between HAT cases and controls showing SNPs with lowest p-Values and SNPs in APOL1 gene.
CHR SNP GENE BP A1 F_A F_U A2 P OR L95 U95 p(HWE) BONF FDR_BH
22 rs71785313 APOL1_G2 36662046 DEL 0.0339 0.1974 INS 1.05E-05�� 0.1427 0.05 0.41 1 0.000685 0.000685
7 rs2069845 IL6 22770149 G 0.2458 0.3491 A 0.04512� 0.6074 0.37 1.0 0.8378 1 0.9519
22 rs136177 APOL1 36661842 G 0.06034 0.03947 A 0.3508 1.563 0.57 4.3 1 1 0.9519
22 rs73885319 APOL1_G1 36661906 G 0.1271 0.1207 A 0.7977 1.061 0.54 2.07 1 1 0.9519
22 rs73885316 APOL1 36661674 A 0.01695 0.01293 C 0.8333 1.316 0.22 7.99 1 1 0.9519
22 rs136174 APOL1 36661536 C 0.02586 0.02212 A 0.8607 1.173 0.28 5.00 1 1 0.9519
Analysis of loci within APOL1 and IL6 for association with HAT. CHR: Chromosome number, SNP: single nucleotide polymorphism dbSNP id, BP: Physical position
(base-pair in GRCh37), A1: Minor allele, A2: Major allele, F_A: Frequency of allele 1 in cases, F_U: Frequency of allele 1 in controls, P: Exact p-value, BONF: Bonferroni
corrected p-value, FDR_BH: false discovery rate, OR: Estimated odds ratio (for A1), CI95: 95% confidence interval of odds ratio, HWE: Hardy-Weinberg Equilibrium p-
value
� P-value significant
�� Bonferroni correction significant
https://doi.org/10.1371/journal.pntd.0007603.t002
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using logistic regression with gender and age as covariates, neither of these covariates had sig-
nificant effects (p> 0.05) (see S6 Table).
An association was observed at APOL1_G2 rs71785313 (Table 2) with an odds ratio of 0.14
(95% CI: 0.05 to 0.41, p = 0.00001). This indicates a substantially reduced susceptibility to T.b.
rhodesiense infection for individuals that possess a G2 variant. No association was found at
APOL1 G1 rs73885319 with T.b. rhodesiense infection (p = 0.80; Table 2). The remaining 15
genes did not show any statistically significant difference in the allele frequencies between
cases and controls as shown in S5 Table.
Discussion
The study looked at 96 SNPs in seventeen genes to test genetic association with HAT in the
northern part of Malawi. The main finding of this study is that the APOL1 G2 variant was
strongly associated with protection against T.b. rhodesiense infection in northern Malawi. This
is the first study to show such an association in Malawi. Our study showed a seven-fold reduced
susceptibility for individuals possessing the APOL1 G2 variant. This is consistent with a two-cen-
tre study in Uganda and Guinea [31] that found a five-fold reduced susceptibility to T.b. rhode-
siense for individuals that possess a single copy of G2 variant but no association with the G1
haplotype and T.b. rhodesiense. However, another study in Uganda found no association
between the G2 allele and T.b. rhodesiense HAT [32]. The two studies in Uganda were conducted
in two very different populations. Cooper et al. [31] found an association in a population from
Kabermaido District of mixed Nilotic and Bantu descent with a G2 allele frequency in controls
of 14.4%, whereas Kimuda and colleagues [32] found no association in a population of Bantu
descent in Busoga district with a G2 frequency of 8.6%. The G2 frequency in this study was
19.7% (Table 2), which is comparable to that in the Kabermaido population in Uganda. How-
ever, the Malawi population is also of Bantu descent and is linguistically and possibly genetically
closer to the Busoga population with low G2 frequency and no association with HAT. Thus, G2
frequencies and association between G2 and HAT do not correlate with the major ethno-linguis-
tic groups. This discrepancy may be due to random genetic drift or specific selection by HAT
and/or other diseases at this locus or to variation in the SRA gene in the different foci.
There was no association between the G1 allele and HAT in Malawi, which is consistent
with both previous studies on T.b. rhodesiense HAT in Uganda [31,32], but this is in contrast
to studies of T.b. gambiense HAT population in Guinea where the G1 allele was protective
[31,60]. An in vitro study also showed that G1 alleles are associated with less lytic potential
than G2 alleles [22].
The seven-fold reduced susceptibility for individuals with APOL1 G2 variant is consistent
with the in vitro evidence of lysis of T.b. rhodesiense by plasma containing the APOL1 G2 allele
and a study that showed that mice with APOL1 G2 survived longer after infection with T.b.
rhodesiense [22,61]. Both the G1 and G2 renal risk variants are in the SRA-interacting domain
of APOL1. The two-amino acid deletion in G2 rs71785313 prevents the binding of SRA to
APOL1 [22,61,62], enabling carriers of the G2 variant to lyse the parasites.
The G1 haplotype consists of two missense mutations in almost perfect linkage disequilib-
rium (rs73885319 and rs60910145). In this study, only rs73885319 was genotyped (Table 2 and
S2 Table), but no association was found with HAT in Malawi.
In conclusion, this study has shown that host genetic polymorphisms play a role in the con-
trol of infections and morbidity in HAT. Of the 17 genes studied, only the APOL1 G2 variant
showed a statistically significant association with T. b. rhodesiense infections after Bonferroni
correction for multiple testing. This is the first study in Malawi to show this association and
increases support for a role for this allele in disease resistance which has previously been found
APOL1 association with Trypanosoma brucei rhodesiense
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associated in one study but not associated in another study. Further studies will be required to
determine the effect of the G1 variant on the severity of T. b. rhodesiense infections and gene
expression between the cases and the controls.
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